ArticleAnnals of medicine2026
Cost-effectiveness of adjuvant therapy with camrelizumab in high-risk locoregionally advanced nasopharyngeal carcinoma: from the perspective of the Chinese healthcare system.
Article in Annals of medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveImmune checkpoint inhibitors, particularly programmed cell death 1 inhibitors, have shown promising clinical outcomes in the adjuvant treatment of locoregionally advanced nasopharyngeal carcinoma (LA-NPC), offering a more effective and less toxic treatment option. This study aimed to explore the cost-effectiveness of adjuvant immunotherapy with camrelizumab for patients with LA-NPC from the perspective of the Chinese healthcare system.
methodsA Markov model was developed to evaluate the health and economic outcomes of adjuvant camrelizumab versus standard therapy (observation) in high-risk LA-NPC. Clinical efficacy and safety data were derived from the phase 3 DIPPER trial. The model incorporated three distinct health states and simulated the outcomes over a lifetime horizon. Key endpoints included overall cost, quality-adjusted life year (QALY), incremental cost-effectiveness ratio (ICER), and incremental net health benefit (INHB), assessed at a predefined willingness-to-pay (WTP) threshold of $39,613 per QALY. One-way and probabilistic sensitivity analyses were conducted to assess the robustness of the model.
resultsCompared with standard therapy, adjuvant camrelizumab for high-risk patients with LA-NPC resulted in an added 4.39 QALYs at an incremental cost of $21,539, yielding an ICER of $4,910/QALY and an INHB of 3.85 QALYs. At the predefined WTP, camrelizumab demonstrated a 98.6% probability of being a cost-effective adjuvant treatment for LA-NPC in China. The health utility value of event-free survival was the most significant parameter influencing the model results. Sensitivity analysis results supported the robustness of the model.
conclusionsIn China, adjuvant immunotherapy with camrelizumab following induction-concurrent chemoradiotherapy offers a potentially cost-effective approach for the management of patients with high-risk LA-NPC, yielding an ICER significantly below the predefined WTP threshold.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.